Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
McKinsey
Johnson and Johnson
Harvard Business School

Last Updated: February 1, 2023

Patents Expiring in April 2034


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Azurity SOTYLIZE sotalol hydrochloride SOLUTION;ORAL 205108-001 Oct 22, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
Azurity SOTYLIZE sotalol hydrochloride SOLUTION;ORAL 205108-001 Oct 22, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
Azurity SOTYLIZE sotalol hydrochloride SOLUTION;ORAL 205108-001 Oct 22, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing Y
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-001 Dec 9, 2016 RX Yes No See Plans and Pricing See Plans and Pricing METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
AstraZeneca
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.